Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

World News: . []

SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No. 15/914,804) describing its equine ulcer treatment product.  The allowed claims recite methods of treating gastrointestinal ulcers using a combination of omeprazole and fenbendazole. 

Adamis already has an issued United States Patent (U.S. 10,137,111) which recites compositions including omeprazole and fenbendazole.  The current allowance strengthens Adamis’ position in the equine treatment market. 

Ulcers are common in the majority of horses that are subject to stress and can affect horses at any age.  Examples of horses under stress include racehorses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse.  In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%.  Historically, ulcers have been known to negatively affect feeding habits and performance on the track.

Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “Sales of our horse ulcer product have continued to grow since we introduced it last year.  We continue to see positive outcomes on horses using our product and we are excited that the intellectual property for this product has expanded.  We recently performed before and after gastric scopes, using our product, at the private racing stable of one of the most prestigious horse farms in the world.  Our product exceeded their expectations and they have moved all their private horses to using our product.  The farm has produced 8 Kentucky Derby winners, 5 Horse of the Year honors, and 2 Triple Crown winners.”

Dr. Carlo also stated, “As we forecasted on the first quarter call, U.S. Compounding continued to improve during the second quarter and we would expect the division to be net positive to Adamis in the second half of 2019.”

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose.  The company’s SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products were approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  In July, Sandoz, a division of Novartis Group, announced it had fully launched both in the U.S.  Please refer to  for additional product information.  Adamis is developing additional products, including a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for patients, animals, hospitals, clinics and surgery centers throughout most of the United States.

More news and information about Adamis Pharmaceuticals Corporation

Published By:

Globe Newswire: 14:00 GMT Wednesday 14th August 2019

Published: .

Search for other references to "adamis" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us